Other ongoing efforts include the phase III MAHOGANY trial studying first-line margetuximab with either retifanlimab (a PD-1 inhibitor) or tebotelimab (a PD-1xLAG-3 bispecific) for metastatic HER2-positive G/GEJ cancers, as well as the phase II/III MOUNTAINEER-2 study evaluating the second-line chemotherapy-free association of tucatinib and trastuzumab [43,71]. Here, ERBB2 is linked to cancer.